BSCG Warns of Reputational Risks from Unregulated Peptides and Research Chemicals

The commercialization of unregulated peptides, injectable compounds, and research chemicals targeting consumers poses a threat to the dietary supplement market, according to an industry warning issued by Oliver Catlin, President of the Banned Substances Control Group (BSCG).¹

In the June 3, 2026, press release, Catlin states that these pharmaceutical substances blur established product distinctions in the minds of consumers while exposing them to risks stemming from an absence of regulatory oversight. Although these unapproved drugs are commonly marketed as dietary supplements, he adds, they do not legally qualify for the category. Furthermore, manufacturers frequently accompany these products with claims regarding injury treatment and anti-aging effects, whereas legitimate supplement brands remain legally restricted to structure-function claims.

“The dietary supplement industry has spent decades building consumer trust around quality, transparency, and responsible formulation,” stated Catlin. “When unapproved peptides, injectable compounds, and research chemicals are marketed in ways that imply they are dietary supplements, the entire category risks losing credibility while consumers are exposed to potential harm and fraudulent marketing.”

Unfair Competition and Market Erosion

The core issue does not lie within the scientific validity of peptides themselves, but rather with their commercialization for consumers and lack of safety verification and regulatory authorization, Catlin clarifies.

Legitimate dietary supplement brands operating under strict Good Manufacturing Practices (GMP) and other compliance requirements are facing unfair competition, he continues. They are competing with gray-market companies selling unapproved compounds without comparable safety, quality, or compliance standards.

What are the Core Concerns Outlined by BSCG?

• Data and Quality Gaps: Peptides and research chemicals are marketed without adequate safety profiles, regulatory authorization, or mandatory quality control.
• Delivery Format Risks: Injectable products are positioned adjacent to ingestible dietary supplements, despite possessing fundamentally disparate risk profiles and characteristics.
• Unsubstantiated Claims: Products are sold with exaggerated performance, recovery, and body-composition assertions lacking regulatory authorization.
• Enforcement Limitations: Inconsistent accountability remains for illegal product offerings containing undeclared or unapproved substances.

Historical Precedents and Collective Action

Catlin highlights that the industry has previously experienced the long-term reputational fallout from illegally marketed, spiked products. Past instances involving designer stimulants, selective androgen receptor modulators (SARMs), PDE-5 inhibitors, and NSAIDs drew public criticism and fostered the perception that the supplement sector is entirely unregulated, he explains. BSCG views the current peptide trend as an identical hazard that could heavily impact legitimate brands in joint health, active nutrition, and wellness segments.

To mitigate these threats and protect consumer confidence, BSCG emphasizes that a renewed focus on transparency, third-party certification, accurate labeling, and stringent regulatory enforcement is critical. “This is a clarion call for responsible brands, retailers, regulators, certification providers, and industry trade groups,” Catlin said. “If the industry stays silent while unregulated research chemicals and enhancement products blur the line with lawful supplements, the long-term damage to consumer confidence and category credibility could be substantial. It is time for us to work together to address this growing concern and protect the legitimate dietary supplement industry.”

Upcoming Public Advisory Committee Meeting Meeting on Peptides

On April 16, 2026, the Food and Drug Administration published a notice announcing a public meeting to be held on July 23 and 24 concerning the inclusion of several peptides (such as BPC-157, KPV, TB-500, and MOTs-C) on the 503A Bulks List for pharmacy compounding.² Public comments for the meeting will be accepted until July 22, 2026.

As BSCG explains, 19 peptides had been placed in Category 2 designation in 2023 because of safety concerns and lack of human clinical data, and in April 2026, 12 unapproved peptides were removed from Category 2, clearing them for Pharmacy Compounding Advisory Committee (PCAC) consideration.³

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Banned Substances Control Group. Anti-doping expert BSCG warns that unregulated peptides and research chemicals threaten the dietary supplement industry. June 3, 2026. Accessed June 11, 2026. https://www.bscg.org/announcements-press-releases/single/anti-doping-expert-bscg-warns-that-unregulated-peptides-and-research-chemicals-threaten-the-dietary-supplement-industry
2. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Notice. Fed Regist. 2026;91(74):20465-20467. FR Doc. 2026-07361. Published April 16, 2026. Accessed June 11, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
3. Banned Substances Control Group. What’s changing with peptide regulation in 2026. May 3, 2026. Accessed June 11, 2026. https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026